Jill Anderson brings more than two decades of leadership and entrepreneurship in oncology services and medical devices to her role as president and CEO of Cianna Medical. She previously served as President of BioLucent where she oversaw the rapid sales growth of the MammoPad breast cushion and Biolucent’s ascendant profile in women’s health care through the company’s acquisition by Hologic, Inc. in 2007. Prior to joining BioLucent, she served as Vice President, Cancer Services at Lehigh Valley Hospital and Health Network, where she led the expansion of the medical oncology service that doubled revenue, and implemented several new areas of service into the hospital’s cancer care program. As Vice President, Eastern Region for Salick Health Care, she was responsible for the company’s entry in the New York City market.
Tiba Aynechi, PhD
Ms. Aynechi is a partner in Novo Ventures, Novo A/S. She has more than 10 years of combined research and banking experience in life sciences that spans various therapeutic areas and technology platforms. Prior to joining Novo A/S, Ms. Aynechi was a Director with Burrill & Company where she has completed regional and cross-border M&A, licensing, and financing transactions for biotech and large pharmaceutical companies. Ms. Aynechi received her PhD from the Graduate Group in Biophysics at the University of California, San Francisco where her research involved developing computational methods for drug discovery. She has an undergraduate degree in physics from the University of California, Irvine. Ms. Aynechi is also a published author of scientific articles and book chapters in the area of rational drug design.
Mr. Busenbark has over 30 years of global experience in the life sciences industry. Prior to joining Cianna Medical, he spent 23 years at Baxter Healthcare,. His experience at Baxter included seven years working as CFO of Immuno AG in Vienna, Austria. He also spent five years as President of Baxter’s global Plasma Therapuetics business. More recently, Mr. Busenbark has served as CFO of three smaller life science companies – Encysive Pharmaceuticals, Xytis Pharmaceuticals and Inspiration Biopharmaceuticals. Mr. Busenbark currently serves as Chief Financial Officer for Cianna Medical.
Ms. Farnsworth is President and CEO of HealthHelp, the first company to offer benefits management for radiology and oncology services. HealthHelp has been named to the Inc. 5000 list of fastest-growing private companies nine times since the year 2000. Ms. Farnsworth is an influential national expert on changing health care regulations and regularly advocates radiology management and health care reform before the Centers for Medicare and Medicaid Services as well as other congressional and regulatory bodies. Farnsworth is a member of the National Quality Forum and serves on several boards including the American Association of PPOs. She also serves on the faculties of the Radiological Society of North America and American Healthcare Radiology Administrators and on the editorial advisory boards of Imaging Economics and Advanced Imaging.
Ms. Olson has been a venture capitalist for 30 years. She is the founder and managing partner of Fog City Fund, a venture fund that invests in life science and medical companies. She was previously a general partner at St. Paul Venture Capital and Sequoia Capital. She has invested in over 40 medical and life sciences companies. She has served as a trustee of UC Berkeley Foundation and of Hampshire College, a director of the San Francisco Opera Association, and a board member of Girl Scouts of San Francisco Bay Area. She is currently a member on University of California Innovation Council established in 2014 by UC President Napolitano to facilitate technology transfer of UC technology and innovations into the state and wider community. She chairs a workgroup for the committee as well as numerous initiatives on the UC Berkeley campus.
David M. Renzi has over 30 years of experience in the healthcare sector. Most recently he was the CEO of Carbylan Therapeutics, a publicly traded company focused on the development of a next generation injectable for treating osteoarthritis pain. Prior to this he was the CEO of Neomend, a commercial developer of sealants and adhesion barrier products utilizing hydrogel technology. David was also the worldwide Vice President of Sales and Marketing and Chief Commercial Officer for Novacept and Surgrx, both privately held venture-backed companies with successful exits. He spent the early half of his career at the Ethicon and Ethicon Endosurgery, divisions of Johnson and Johnson where he was given responsibility for numerous business disciplines to include sales, sales management, marketing management and new procedure development.
Zack Scott, MD
Dr. Scott joined Saints Capital in 2008 and is a Vice President focused on healthcare opportunities. He is currently a board member at Cianna Medical and VisionCare. Prior to Saints, Dr. Scott was at Burrill & Co. where he made healthcare investments for three and a half years. Dr. Scott has invested in the areas of medical devices, health care services, diagnostics and biopharmaceuticals. Previously, Dr. Scott was a General Surgery resident at Oregon Health Science University in Portland, Oregon. Dr. Scott has a BA in Economics from Duke University, an MD from the University of Texas Health Science Center at San Antonio, and an MBA and a certificate in Health Sector Management from the Fuqua School of Business at Duke University, where he was Fuqua Scholar. Dr. Scott is a member of the Alpha Omega Alpha Medical Honor Society.
Mr. Umbel has more than 30 years of medical device and diagnostics leadership experience. Mr. Umbel has lead a start-up company through a successful acquisition and managed large organizations through significant growth. He is currently Vice President of Business Development for Bioventus, a privately owned ortho-biologics company spun out from Smith & Nephew. Prior this Mr. Umbel was Group Senior Vice President, Corporate Development and Marketing for Hologic, Inc., the largest dedicated Women’s Health company in the US.